Printer Friendly

HLA-G dimers in the prolongation of kidney allograft survival.

1. Introduction

Human leukocyte antigen-G (HLA-G) is a natural molecule involved in the establishment and maintenance of maternal tolerance to semiallogeneic fetal tissues [1-6]. Decreased expression of HLA-G during pregnancy has been noted as a contributing factor to preeclampsia and multiple miscarriages [7-11]. In addition, HLA-G expression has been identified in pancreas, adult thymic cells, and stem cells, as well as in pathological conditions including cancer, transplantation, HIV infection, and inflammatory diseases [12-27]. HLA-G binds to several receptors, including ILT2, ILT4, and KIR2DL4 receptors, to inhibit immune responses of myelomonocytic cells, dendritic cells, T cells, B cells, and NK cells [5, 28-35]. In addition to membrane-bound forms (HLA-G1, -G2, -G3, and -G4), HLA-G is also presented by several soluble isoforms (sHLA-G1, -G5, -G6, and -G7) generated through two mechanisms: alternative splicing and proteolytic release, which is known to be mediated by metalloproteases [36, 37]. Significantly high levels of sHLA-G were determined in several physiological and pathological conditions, including an association with higher pregnancy and implantation rates [8]. It has been determined that a high level of sHLA-G is correlated with clinical manifestation of several diseases, rheumatoid arthritis, systemic lupus erythematosus, asthma, and HIV infection. Increased levels of sHLA-G were correlated with disease progression in patients with hematological malignancies and solid tumors, including patients with acute leukemia, lymphoma, chronic lymphatic leukemia, melanoma, breast cancer, glioma, and renal and lung carcinomas [25, 38]. Recent studies showed that sHLA-G molecules are involved in prolongation of allograft survival in patients with organ/tissue transplantation [39-41]. In most studies plasma/serum levels of HLA-G was determined by ELISA. However, HLA-G-specific ELISA has limitations and does not discriminate the presence of monomer or dimer isoforms of HLA-G. New data has revealed that disulfide-linked dimeric complexes of HLA-G have high preferential binding to immune inhibitory receptors, induce efficient immune inhibitory receptor signaling, and have strong functional activities [32, 42-45]. Limited data are available on the role of HLA-G dimers in clinical pathological conditions. The outstanding questions are whether these HLA-G dimers are formed in patients with organ transplantation and what their function might be in the prolongation of allograft survival. Here we report the analysis of sHLA-G dimers in kidney transplant patients. First, we determined that the levels of sHLA-G dimers were significantly higher in patients with no rejection episode compared with patients that have a chronic rejection of a kidney transplant. The high levels of sHLA-G dimers were associated also with increased expression of the membrane-bound form of HLA-G on monocytes from patients that have no rejection episode of kidney transplant.

HLA-G also has the ability to reduce inflammatory responses through the inhibition of immune cells to produce proinflammatory molecules. One of the potential candidates of such molecules includes matrix metalloproteinase (MMP). Increased expression of MMPs was observed in several human diseases, including cancer and autoimmune diseases, suggesting an involvement of these enzymes in immunity, inflammatory responses, and repair mechanisms. MMP-9 and MMP-2 are especially able to modulate inflammatory responses via cytokine/chemokine actions. Here we demonstrated that the high levels of sHLA-G dimers in kidney transplant patients that have no episodes of rejection were associated with decreased plasma levels of MMP-9. We also determined that the increased levels of sHLA-G dimers linked to the lower levels of proinflammatory cytokines, suggesting the potential role of sHLA-G dimers in controlling the accompanying inflammatory state. From these findings, sHLA-G dimers might be useful as a potential marker to control rejection and the inflammatory status of human kidney allotransplants.

2. Materials and Methods

2.1. Patients. We enrolled kidney transplant recipients in the study, of which 50 had no evidence of rejection (NR) and 17 had chronic rejection (CR). Kidney function and rejection was evaluated by creatinine level and verified by biopsy. Table 1 describes the clinical and demographic characteristics of the patient population. Kidney recipients in both categories had similar distribution with respect to gender, age, and race. The distribution of donor source (living or deceased), cold ischemia time, primary cause of renal failure, and immunosuppressive treatment between each group of recipients was not statistically different. Average creatinine levels of CR patients were significantly higher than NR patients (P < 0.05). The protocol was approved by the Human Assurance Committee of Georgia Regents University, and written informed consent was obtained from all subjects in the study.

2.2. Separation of Human Plasma, PBMCs, and Red Blood Cells from Whole Blood. Blood samples were obtained from patients and collected in EDTA tubes. Aliquots of plasma were stored at -80[degrees]C. PBMCs and red blood cells were isolated from buffy coats using Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA) gradient centrifugation. Aliquots of PBMCs were stored in liquid nitrogen. Aliquots of red blood cells were stored at -80[degrees]C.

2.3. Zymography. Total protein of plasma samples was measured using the Bradford method (Bio-Rad, Richmond, CA, USA). Diluted (1: 50) plasma samples were loaded onto 10% gelatin gels, and electrophoresis was performed at 100 constant voltages. Gels were washed twice with 2.5% TritonX for 20 min and then incubated at 37[degrees]C overnight in zymography Development Buffer (Bio-Rad). The following day, to visualize the bands, gels were stained with Coomassie Brilliant Blue Dye (Bio-Rad) for 3hrs and destained with Destaining Solution for 45 min. The gels were rehydrated in water overnight, then scanned and analyzed using ImageJ program developed at the National Institutes of Health (USA).

2.4. Depletion of Albumin and IgG from Plasma before Immunoprecipitation. Depletion of unwanted proteins that could interfere with the immunoprecipitation of HLA-G from plasma was achieved using ProteoPrep Immunoaffinity Albumin and IgG Depletion kit (Sigma-Aldrich) following the manufacturer's protocol.

2.5. Immunoprecipitation of Depleted Plasma and Western Blot Analysis for Detection of HLA-G Monomer and Dimer. 100 [micro]L of depleted plasma were mixed with 100 [micro]L of cold RIPA buffer and incubated on ice for 15 min. 20 [micro]L of protein G bead slurry was added to the plasma lysate, then incubated at 4[degrees]C for 60 min and centrifuged at 10,000 g for 10 min. 2 [micro]L of MEM-G/9 mAb (Santa Cruz Biotechnology, Dallas, TX, USA) was added to the supernatant and the mixture was incubated at 4[degrees]C overnight. After incubation, 50 [micro]L of Protein G bead slurry was added to the plasma lysate, incubated at 4[degrees]C for 1hr, and centrifuged at 10,000 g for 30 sec. 50 [micro]L of Laemmli sample buffer was added to the bead pellet. Samples were run under both reduced and nonreduced conditions. The mixture was denatured at 95[degrees]C for 5 min and centrifuged at 10,000 g for 5 min. The supernatant was loaded onto gels for electrophoresis. 30 [micro]L of immunoprecipitated plasma was separated on 10% running gel and 5% stacking gel and transferred to PVDF membrane. The membrane was blocked with 5% BSA and incubated with MEM-G/9 primary mAb, followed by goat anti-mouse IgG-HRP secondary Ab (Santa Cruz Biotechnology). Chemiluminescent HRP-conjugated detection reagent was used for detection. Quantification of blotted proteins was determined by densitometry analysis of scanned films using ImageJ software.

2.6. Cytokine and Chemokine Analysis. Cytokine and chemokine plasma levels were measured using the Multi-Analyte ELISArray Kits (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendations. The Array Kits are designed for the simultaneous detection of up to 12 pro- and anti-inflammatory cytokines and chemokines (IL1[alpha], IL1[beta], IL2, IL4, IL6, IL8, IL10, IL12, IL17A, IFN[gamma], TNF[alpha], and GM-CSF).

2.7. Flow Cytometry. PBMCs from both groups of patients (NR and CR) were treated with human TruStain FcX (Fc receptor blocking solution; BioLegend, San Diego, CA, USA) and stained using fluorochrome-conjugated human-specific mAbs against CD3, CD4, CD8, CD14, CD19, and HLA-G. All mAbs were purchased from BD Biosciences (San Jose, CA, USA) or from BioLegend. Cytometry was performed on a cytometer FACSCanto (BD, Franklin Lakes, NJ, USA) and data were analyzed using FlowJo software (Tree Star Inc, Ashland, OR, USA) or Cell Quest software (BD Biosciences). Some results are expressed as percentage of positive cells obtained with specific Ab compared to irrelevant isotype-matched Ab.

2.8. Statistical Analysis. Statistical analysis was performed using NCSS (NCSS LLC, Kaysville, Utah, USA) and GraphPad (GraphPad Inc., La Jolla, CA, USA) packages. Normality and continuous numeric data was checked using the Kolmogorov-Smirnoff one-sample test, and comparisons were performed by Student's t test or by Mann-Whitney U test when appropriate. The P value of [less than or equal to] 0.05 was considered to be statistically significant.

3. Results

3.1. The Levels of sHLA-G1/HLA-G5 Monomer and Dimer Forms Are Increased in Plasma of Nonrejected Kidney Transplant Patients. In this study we evaluated the levels of monomer and dimer forms of sHLA-G1 and HLA-G5 isoforms in patients with nonrejected (NR) and chronic rejected (CR) kidney allografts. Immunoprecipitation and Western blot analysis of plasma patients resulted in the discovery of two bands; one corresponding to the expected molecular mass of 39 kDa, which represents the sHLA-G monomer, and one approximately twice that (sHLA-G dimer) (Figure 1(a)). The supernatant from HLA-G5-transfected 721.221 human lymphoblastoid cells was used as a positive control. Both forms of sHLA-G had been determined in the plasma of NR and CR patients, and there was considerable variation in sHLA-G levels within each group. However, the level of total sHLA-G was significantly higher (P = 0.03) in NR compared with CR kidney transplant patients (Figure 1(b)). In addition, the level of the monomer form of sHLA-G was slightly higher in the NR group compared with the CR group (Figure 1(c)). We determined that the dimer form of sHLA-G was dominant in the plasma of both groups of patients. Moreover, the level of the dimer form of sHLA-G was significantly elevated (P = 0.03) in the NR group of patients (Figure 1(d)). These data indicate that the dimer form of sHLA-G is present and dominates in the plasma of kidney transplant patients.

3.2. Increased Expression of the Membrane-Bound Form of HLA-G1 in Monocytes from Nonrejected Kidney Transplant Patients. It is known that sHLA-G proteins can be generated by two mechanisms: alternative splicing and proteolytic release, which is mediated by metalloproteases. To determine the potential contribution of the membrane-bound form of HLA-G1 shedding into the pool of sHLA-G molecules in plasma patients, the expression of HLA-G1 on the cell surface of peripheral monocytes and T and B cells has been analyzed in both groups of patients. There was no significant difference in the number of HLA-G1-positive T cells and B cells between NR and CR patients (Figures 2(a) and 2(d) and data not shown). Overall, in both groups of patients, HLA-G1-positive cells represent a small fraction (2-6% of the total) of T and B cells. As expected, the majority of HLA-G1-positive cells in the peripheral blood of both NR and CR patients were determined in the population of monocytes (Figures 2(a), 2(b),and 2(c)). However, the number of HLA-G1-positive monocytes was significantly elevated (P = 0.002) in the NR patients, but not in the CR patients (Figure 2(e)). These data revealed that the increased expression of HLA-G1 on monocytes from NR patients might have a substantial contribution to the elevated plasma levels of sHLA-G monomer and dimer forms in those patients.

3.3. Analysis of MMP-2 and MMP-9 in Plasma of NR and CR Kidney Transplant Patients. Since one of the mechanisms of the production of sHLA-G involves shedding of the membrane-bound form of HLA-G1 by metalloproteases and since MMPs play a crucial role this class of enzymes, we investigated the levels of MMP-2 and MMP-9 in the plasma of kidney transplant patients. Zymography analysis of transplant patients showed the presence of two bands at 68 kDa and 90 kDa, which correspond to MMP-2 and MMP9, respectively (Figure 3(a)). As shown in Figure 3(a), plasma from both groups of patients contains substantial amounts of MMP-2 and MMP-9, with no significant difference in the plasma levels of MMP-2 and MMP-9 between NR and CR patients (Figures 3(c) and 3(d)). However, a tendency toward elevation of MMP-9 levels was observed in the CR kidney transplant patients (Figure 3(d)). Since plasma from both the NR and CR groups of patients contains sHLA-G, this data additionally support the possibility that MMPs might play a role in contributing to the pool of total sHLA-G by shedding the membrane-bound HLA-G1 molecules.

Since HLA-G, MMP-2, and MMP-9 are all involved in regulation of the inflammatory response by modulation of cytokines and chemokines and the inflammatory response represents a critical stage in rejection or survival of allogeneic transplants, we next determined the levels of proinflammatory cytokines in kidney transplant patients.

3.4. Increased Levels of Proinflammatory Cytokines IL-1p, IL-2, and IL-6 in Plasma from Patients with Chronic Rejection of Kidney Transplant. We thus investigated whether the plasma level of proinflammatory cytokines differs between NR and CR kidney transplant patients. For this purpose, we have used a Multi-Analyte ELISArray Kits designed to simultaneously assess the levels of 12 pro- and anti-inflammatory cytokines and chemokines (IL1[alpha], IL1[beta], IL2, IL4, IL6, IL8, IL10, IL12, IL17A, IFN[gamma], TNF[alpha], and GM-CSF). There was considerable variation in cytokines levels within both the NR and CR patients, especially for IL-1[alpha], IL-4, IL-12, and IFN[gamma] (Figure 4). However, the CR kidney transplant patients had significantly elevated levels of proinflammatory cytokines IL-2 (P = 0.005), IL-1[beta] (P = 0.05), and IL-6 (P = 0.05) (Figure 4). In addition, the level of IL-17A was elevated in CR patients. These data support our observation that the dimer form of sHLA-G associates with control of inflammatory responses in kidney transplants patients.

4. Discussion

HLA-G is natural molecule involved in the establishment and maintenance of maternal tolerance to fetal semiallogeneic tissues. HLA-G binds to several immune cell inhibitory receptors, for example, ILT2, ILT3, and ILT4, to down-modulate immune responses of myelomonocytic cells, T cells, B cells, and NK cells. Limited polymorphisms, restricted tissue expression, and a relatively restricted peptide presentation make HLA-G a unique molecule, unlike the classical HLA class I molecules. Recently, another unusual characteristic of HLA-G has been discovered: its ability to form a disulfide-linked dimer form both in solution and at the cell surface. HLA-G, unlike most other MHC class I molecules, has two free cysteine residues located in positions 42 and 147 in extracellular domains [alpha]1 and [alpha]2, respectively. HLA-G molecules refolded in vitro form a disulfide-linked dimer with an intermolecular Cys42-Cys42 disulfide bond [46]. Soluble HLA-G5 molecules expressed by human 293 T cells also form disulfide-linked dimeric and additional oligomeric forms, which can reduce the level of CD8 expression on cytotoxic T lymphocytes (CTLs) [47]. The efficiency of inhibitory signaling is dependent upon several factors, including the stability and avidity of the ligand and its proper structural orientation, which significantly affects the affinity and signaling to targeted inhibitory receptors. Mutagenesis studies of the free cysteines suggested that the HLA-G dimer more efficiently inhibits NK killing than the monomer and increases the efficiency of ILT2 signaling [32, 42, 43, 48]. Experimental data from several groups, including our laboratory, suggest that HLA-G dimer has increased avidity and proper structural orientation to induce efficient inhibitory signaling during ligation with human ILT2 and ILT4, and murine PIR-B-inhibitory receptors [32, 44, 45]. This makes HLA-G dimer as the most powerful ligand form for modulation of inflammatory and alloimmune responses in several pathological conditions, including the prolongation of kidney allograft survival or graft acceptance. Many studies have been designed to determine sHLA-G in the plasma or serum of patients suffering from various diseases. sHLA-G levels were determined in spontaneous miscarriages, in autoimmune diseases, in solid organ transplantation, and in various malignancies. In almost all the studies, the quantification of sHLA-G was analyzed using ELISA. Unfortunately, the available sHLA-G ELISA determines the total amount of sHLA-G protein only, which includes both monomer and dimer forms. Since the dimer represents the most powerful form of sHLA-G, it is very critical to analyze the levels of sHLA-G dimer in healthy and disease conditions. To date, no study has investigated whether HLA-G disulfide-linked homodimers are present in plasma from kidney transplant patients. Here we show that sHLA-G dimers are present in plasma from kidney transplant patients. The levels of sHLA-G dimer were significantly elevated in patients with no rejection episodes compared with patients with chronic rejection, indicating the association of sHLA-G dimers with the prolongation of kidney allograft survival. In support of that, similar levels of expression and percent of immune inhibitory receptor ILT2- and ILT4-positive cells has been determined on monocytes and T and B cells in both groups of patients (data not shown). This clinical finding is in agreement with our previous study using animal models demonstrating that HLA-G dimers prolong the survival of allogeneic skin transplants in ILT transgenic mice ([32, 49, 50] and unpublished data). In the future, it will be important to determine the percentages of sHLA-G1 and sHLA-G5 dimers in total sHLA-G. However, to date, there is no data available demonstrating that sHLA-G1 and sHLA-G5 dimers have different binding and/or different efficiency to induce inhibitory receptor signaling. Our results show that the number of HLA-G1-positive monocytes is significantly increased in NR patients, indicating that the percent of sHLA-G1 dimer might have been elevated within the total level of sHLA-G dimers in plasma of the patients with no episodes of rejection. Recently, Rizzo et al. [37] demonstrated an effective link between mMp-2 and HLA-G1 shedding in 721.221-G transfected cell line, JEG3 cell line, and IL-10-treated PBMCs from five healthy donors using an in vitro experiments. However, the process of shedding and especially dimerization of sHLA-G1 in vivo and in pathological conditions, including kidney transplant patients, could be affected by several factors and requires additional investigation.

The anti-inflammatory effects of sHLA-G dimers represent a new finding for this form of HLA-G. Recently published data by Kuroki et al. [45] demonstrating that in an animal model of collagen-induced arthritis, HLA-G dimer interacting through a murine ILT homologue, the PIRB receptor exhibited significantly more anti-inflammatory effects compared to monomer. To date, no data is available on studies of the anti-inflammatory effect of sHLA-G dimers in clinical applications. We demonstrate here that an increased level of sHLA-G dimers in kidney transplant patients with no rejection episodes is linked to significantly lower levels of proinflammatory cytokines IL-2, IL-1[beta], and IL-6. It will be important to dissect the mechanisms of sHLA-G dimers controlling inflammatory responses. The anti-inflammatory effect of sHLA-G dimers opens a new strategy to generate useful agents to control inflammatory responses with minimal side effects.

In conclusion, our study shows that sHLA-G dimers are associated with better survival of kidney allografts and control of the accompanying inflammatory response in kidney transplant patients. Thus sHLA-G dimers can be a potential biomarker to control human alloimmune and inflammatory responses.

http://dx.doi.org/10.1155/2014/153981

Conflict of Interests

The authors declare that there is no potential conflict of interests.

Acknowledgments

The authors thank Walidah Walker for the assistance on data collection. They thank Dr. Rhea-Beth Markowitz for discussion and assistance. This work was supported by the Carlos and Marguerite Mason Trust.

References

[1] N. Rouas-Freiss, R. M.-B. Gonsalves, C. Menier, J. Dausset, and E. D. Carosella, "Direct evidence to support the role of HLAG in protecting the fetus from maternal uterine natural killer cytolysis," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11520-11525, 1997.

[2] M. Ponte, C. Cantoni, R. Biassoni et al., "Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5674-5679, 1999.

[3] E. D. Carosella, P Moreau, J. le Maoult, M. le Discorde, J. Dausset, and N. Rouas-Freiss, "HLA-G molecules: from maternal-fetal tolerance to tissue acceptance," Advances in Immunology, vol. 81, pp. 199-252, 2003.

[4] J. S. Hunt, M. G. Petroff, R. H. McIntire, and C. Ober, "HLA-G and immune tolerance in pregnancy," The FASEB Journal, vol. 19, no. 7, pp. 681- 693, 2005.

[5] R. Apps, L. Gardner, and A. Moffett, "A critical look at HLA-G," Trends in Immunology, vol. 29, no. 7, pp. 313-321, 2008.

[6] E. D. Carosella, B. Favier, N. Rouas-Freiss, P Moreau, and J. Lemaoult, "Beyond the increasing complexity of the immunomodulatory HLA-G molecule," Blood, vol. 111, no. 10, pp. 4862-4870, 2008.

[7] P Moreau, L. Contu, F. Alba et al., "HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage," Biology of Reproduction, vol. 79, no. 3, pp. 459- 467, 2008.

[8] R. Rizzo, A. S. Andersen, M. R. Lassen et al., "Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy," American Journal of Reproductive Immunology, vol. 62, no. 5, pp. 320-338, 2009.

[9] M. H. Larsen, M. Bzorek, M. B. Pass et al., "Human leukocyte antigen-G in the male reproductive system and in seminal plasma," Molecular Human Reproduction, vol. 17, no. 12, pp. 727-738, 2011.

[10] M. Dahl and T. V. F. Hviid, "Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss," Human Reproduction Update, vol. 18, no. 1, pp. 92-109, 2012.

[11] D. A. Loisel, C. Billstrand, K. Murray et al., "The maternal HLA-G1597AC null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women," Molecular Human Reproduction, vol. 19, no. 3, pp. 144-152, 2013.

[12] E. D. Carosella, P. Moreau, S. Aractingi, and N. Rouas-Freiss, "HLA-G: a shield against inflammatory aggression," Trends in Immunology, vol. 22, no. 10, pp. 553-555, 2001.

[13] V. Cirulli, J. Zalatan, M. McMaster et al., "The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G," Diabetes, vol. 55, no. 5, pp. 1214-1222, 2006.

[14] L. Crisa, M. T. McMaster, J. K. Ishii, S. J. Fisher, and D. R. Salomon, "Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts," The Journal of Experimental Medicine, vol. 186, no. 2, pp. 289- 298, 1997.

[15] F. Morandi, L. Raffaghello, G. Bianchi et al., "Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens," Stem Cells, vol. 26, no. 5, pp. 1275-1287, 2008.

[16] O. Baricordi, M. Stignani, L. Melchiorri, and R. Rizzo, "HLAG and inflammatory diseases," Inflammation & Allergy-Drug Targets, vol. 7, no. 2, pp. 67-74, 2008.

[17] P Schutt, V. Rebmann, D. Brandhorst et al., "The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients," Human Immunology, vol. 69, no. 2, pp. 79-87, 2008.

[18] A. Verloes, H. van de Velde, J. LeMaoult et al., "HLA-G expression in human embryonic stem cells and preimplantation embryos," The Journal of Immunology, vol. 186, no. 4, pp. 2663-2671, 2011.

[19] R. Rizzo, M. Vercammen, H. van de Velde, P. A. Horn, and V. Rebmann, "The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells," Cellular and Molecular Life Sciences, vol. 68, no. 3, pp. 341-352, 2011.

[20] L. Amiot, S. Ferrone, H. Grosse-Wilde, and B. Seliger, "Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?" Cellular and Molecular Life Sciences, vol. 68, no. 3, pp. 417- 431, 2011.

[21] S. Agaugue, E. D. Carosella, and N. Rouas-Freiss, "Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17," Blood, vol. 117, no. 26, pp. 7021-7031, 2011.

[22] S. Zilberman, C. Schenowitz, S. Agaugue et al., "HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment," European Journal of Immunology, vol. 42, no. 6, pp. 1599-1608, 2012.

[23] A. Naji, C. Menier, G. Maki, E. D. Carosella, and N. Rouas-Freiss, "Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction," Leukemia, vol. 26, no. 8, pp. 1889-1892, 2012.

[24] F. Morandi, P. Scaruffi, F. Gallo et al., "Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-g proteins," PLoS ONE, vol. 7, no. 1, article e29922, 2012.

[25] G. Curigliano, C. Criscitiello, L. Gelao, and A. Goldhirsch, "Molecular pathways: human leukocyte antigen G (HLA-G)," Clinical Cancer Research, vol. 19, no. 20, pp. 5564-5571, 2013.

[26] V. Pistoia, F. Morandi, G. Bianchi, A. Pezzolo, I. Prigione, and L. Raffaghello, "Immunosuppressive microenvironment in neuroblastoma," Frontiers in Oncology, vol. 3, article 167, 2013.

[27] I. J. Wastowski, R. T. Simoes, L. Yaghi et al., "Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-y treatments: results from a multicentric study," The American Journal of Pathology, vol. 182, no. 2, pp. 540-552, 2013.

[28] S. Liang, B. Baibakov, and A. Horuzsko, "HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor," European Journal of Immunology, vol. 32, no. 9, pp. 2418-2426, 2002.

[29] S. Liang and A. Horuzsko, "Mobilizing dendritic cells for tolerance by engagement of immune inhibitory receptors for HLA-G," Human Immunology, vol. 64, no. 11, pp. 1025-1032, 2003.

[30] J. LeMaoult, K. Zafaranloo, C. le Banff, and E. D. Carosella, "HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells," The FASEB Journal, vol. 19, no. 6, pp. 662-664, 2005.

[31] V. Ristich, S. Liang, W. Zhang, J. Wu, and A. Horuzsko, "Tolerization of dendritic cells by HLA-G," European Journal of Immunology, vol. 35, no. 4, pp. 1133-1142, 2005.

[32] S. Liang, V. Ristich, H. Arase, J. Dausset, E. D. Carosella, and A. Horuzsko, "Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8357-8362, 2008.

[33] W. Zhang, S. Liang, J. Wu, and A. Horuzsko, "Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts," Transplantation, vol. 86, no. 8, pp. 1125-1134, 2008.

[34] C. Li, B. L. Houser, M. L. Nicotra, and J. L. Strominger, "HLAG homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 14, pp. 5767-5772, 2009.

[35] S. Rajagopalan and E. O. Long, "[KIR2DL.sub.4] ([CD.sub.15]8d): an activation receptor for HLA-G," Frontiers in Immunology, vol. 3, article 258, 2012.

[36] I. Zidi, C. Guillard, C. Marcou et al., "Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-[kappa]B inducers," Cellular and Molecular Life Sciences, vol. 63, no. 22, pp. 2669-2681, 2006.

[37] R. Rizzo, A. Trentini, D. Bortolotti et al., "Matrix metalloproteinase- (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding," Molecular and Cellular Biochemistry, vol. 381, no. 1-2, pp. 243-2255, 2013.

[38] P. Schutt, B. Schutt, M. Switala et al., "Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients," Human Immunology, vol. 71, no. 5, pp. 489-495, 2010.

[39] J. Qiu, P. I. Terasaki, J. Miller, K. Mizutani, J. Cai, and E. D. Carosella, "Soluble HLA-G expression and renal graft acceptance," American Journal of Transplantation, vol. 6, no. 9, pp. 2152-2156, 2006.

[40] S. le Rond, C. Azema, I. Krawice-Radanne et al., "Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells," The Journal of Immunology, vol. 176, no. 5, pp. 3266-3276, 2006.

[41] J. Luque, M. I. Torres, M. D. Aumente et al., "Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy," Human Immunology, vol. 67, no. 4-5, pp. 257-263, 2006.

[42] T. Gonen-Gross, H. Achdout, R. Gazit et al., "Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function," The Journal of Immunology, vol. 171, no. 3, pp. 1343-1351, 2003.

[43] M. Shiroishi, K. Kuroki, L. Rasubala et al., "Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d)," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16412-16417, 2006.

[44] M. Shiroishi, K. Kuroki, T. Ose et al., "Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer," The Journal of Biological Chemistry, vol. 281, no. 15, pp. 10439-10447, 2006.

[45] K. Kuroki, K. Hirose, Y. Okabe et al., "The long-term immunosuppressive effects of disulfide-linked HLA-G dimer in mice with collagen-induced arthritis," Human Immunology, vol. 74, no. 4, pp. 433-438, 2013.

[46] J. E. Boyson, R. Erskine, M. C. Whitman et al., "Disulfide bond-mediated dimerization of HLA-G on the cell surface," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16180-16185, 2002.

[47] P. J. Morales, J. L. Pace, J. S. Platt et al., "Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype," The Journal of Immunology, vol. 171, no. 11, pp. 6215-6224, 2003.

[48] T. Gonen-Gross, R. Gazit, H. Achdout et al., "Special organization of the HLA-G protein on the cell surface," Human Immunology, vol. 64, no. 11, pp. 1011-1016, 2003.

[49] K. Y. Howangyin, M. Loustau, J. Wu et al., "Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors," Cellular and Molecular Life Sciences, vol. 69, no. 23, pp. 4041-4049, 2012.

[50] J. Lemaoult, M. Daouya, J. Wu, M. Loustau, A. Horuzsko, and E. D. Carosella, "Synthetic HLA-G proteins for therapeutic use in transplantation," The FASEB Journal, vol. 27, no. 9, pp. 3643-3651, 2013.

Maureen Ezeakile, (1) Vera Portik-Dobos, (1) Juan Wu, (1) Daniel D. Horuzsko, (1) Rajan Kapoor, (2) Muralidharan Jagadeesan, (2) Laura L. Mulloy, (2) and Anatolij Horuzsko (1)

(1) Molecular Oncology and Biomarkers Program, Cancer Center, Department of Medicine, Georgia Regents University, 1410 Laney Walker Boulevard, Augusta, GA 30912, USA

(2) Section of Nephrology, Hypertension, and Transplantation Medicine, Department of Medicine, Georgia Regents University, Augusta, GA 30912, USA

Correspondence should be addressed to Anatolij Horuzsko; ahoruzsko@gru.edu

Received 8 December 2013; Revised 23 February 2014; Accepted 27 February 2014; Published 30 March 2014

Academic Editor: Enrico Fainardi

TABLE 1: Demographic, clinical, therapeutic, and transplant-related
parameters of the patients.

                          NR                     CR

Total, n                  50                     17
Gender, n
Male                      14                     4
Female                    36                     13
Recipient age, yr,        51.28 (24-75)          4794 (27-75)
  mean (range)
Race, % (n)
Caucasian                 26% (13)               29.4% (5)
African American          70% (35)               64.7% (11)
Hispanic                  4% (2)                 5.9% (1)
Primary cause of
  renal failure, n
Diabetic nephropathy      15                     3
Lupus nephritis           --                     3
Renal cystic disease      6                      1
Glomerulosclerosis        5                      1
Hypertension              11                     3
Hypertensive              3                      2
  kidney disease
Other                     14                     4
Donor type, % (n)
Deceased                  80% (40)               70.6% (12)
Living                    20% (10)               29.4% (5)
Cold ischemia time, hr,   16.00 [+ or -] 10.01   14.57 [+ or -] 0.39
  mean [+ or -] SD          (n = 45)               (n = 13)
Immunosuppressive         1.48 (0.79-2.56)       2.71 (1.04-6.46)
  treatment, n
(HLA-A, B, DRB1)          1.83 [+ or -] 0.71     2.08 [+ or -] 0.66
  matches,                  (n = 36)               (n = 13)
  mean [+ or -] SD
(HLA-A, B, DRB1)          1.42 [+ or -] 0.71     3.62 [+ or -] 0.70
  mismatches,               (n = 36)               (n = 13)
  mean [+ or -] SD
Immunosuppressive
  treatment, n
Azathioprine              2                      --
Cyclosporine              5                      4
Mycophenolate             30                     14
Prednisone                34                     13
Rapamycin (Sirolimus)     5                      3
Tacrolimus                36                     9

NR: no rejection; CR: chronic rejection.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article; Human leukocyte antigen-G
Author:Ezeakile, Maureen; Portik-Dobos, Vera; Wu, Juan; Horuzsko, Daniel D.; Kapoor, Rajan; Jagadeesan, Mur
Publication:Journal of Immunology Research
Article Type:Report
Date:Jan 1, 2014
Words:5277
Previous Article:Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy.
Next Article:Regulatory lymphocytes are key factors in MHC-independent resistance to EAE.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters